Gaithersburg, MD – April 6, 2020: MaxCyte, a global cell-based therapies and life sciences company, today announced that CEO Doug Doerfler plans to present an overview of the company and provide a business update at the upcoming Solebury Trout Virtual Global Healthcare Series. During the 25-minute presentation, participants will be able to submit questions electronically with answers provided by the company on an individual basis afterwards. Details are as follows:
| Date/Time: Tuesday, April 7, 2020, at 10:30 a.m. EDT To access the presentation, please login HERE: https://78449.themediaframe.com/dataconf/productusers/solebury/mediaframe/36850/indexl.html |
About MaxCyte
MaxCyte, the clinical-stage global cell-based therapies and life sciences company, uses its proprietary next-generation cell and gene therapies to revolutionize medical treatments and ultimately save lives. The Company’s premier cell engineering enabling technology is currently being deployed by leading drug developers worldwide, including all of the top ten global biopharmaceutical companies. MaxCyte licenses have been granted to more than 100 cell therapy programmes, with more than 70 licensed for clinical use, and the Company has now entered into nine clinical/commercial license partnerships with leading cell therapy and gene editing developers. MaxCyte was founded in 1998 and is headquartered in Gaithersburg, Maryland. For more information, visit www.maxcyte.com
For further information, please contact:
| MaxCyte Inc.
Doug Doerfler, Chief Executive Officer Ron Holtz, Chief Financial Officer
US Investor Relations Michael Levitan Solebury Trout +1 646 378 2920 mlevitan@soleburytrout.com
US Media Relations Jamie Lacey-Moreira PressComm PR, LLC +1 410-299-3310 jamielacey@presscommpr.com
|
+1 301 944 1660 |